Rhythm Pharmaceuticals (RYTM) stock has been in focus after the FDA approved an expanded use of IMCIVREE for acquired hypothalamic obesity in patients as young as four. This decision broadens its treated population.

The latest FDA approval, the positive European opinion on IMCIVREE and recent board changes have come alongside a 7 day share price return of 13.81%, while the 90 day share price return of 17.83% and very large 3 year total shareholder return suggest longer term momentum has already been significant.

If you are looking beyond a single rare disease name, it could be a good time to see which other healthcare names are gaining attention through our 36 healthcare AI stocks

With Rhythm shares at US$86.29, an intrinsic value estimate implying an 80% discount, and a price target that sits well above the current level, investors now face a key question: Is there still a buying opportunity here, or has the market already priced in future growth?

Most Popular Narrative: 37.1% Undervalued

Rhythm Pharmaceuticals' most followed narrative pegs fair value at $137.27 per share versus the last close at $86.29. This frames a wide valuation gap that hinges on how IMCIVREE and the broader MC4R franchise perform over time.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader-Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years.

Curious what kind of revenue trajectory, margin shift, and future earnings multiple are baked into that fair value? The narrative leans on aggressive growth, rising profitability, and a premium valuation that would usually be reserved for market leaders in faster growing sectors.

Result: Fair Value of $137.27 (UNDERVALUED)

However, there is still meaningful risk here, including ongoing operating losses of US$201.9m and a heavy reliance on IMCIVREE as the core revenue driver.

Another View: Price To Sales Tells A Different Story

While the SWS DCF model suggests Rhythm is trading at a very large discount to an estimated future cash flow value of $427.51 per share, the current P/S ratio of 31.1x is far higher than the fair ratio of 17.3x, the US Biotechs average of 11x, and peer average of 7.2x. For you as an investor, that gap points to valuation risk if sentiment or growth expectations ease. The key question is which signal carries more weight in your framework.

Next Steps

All this optimism only matters if it matches your own view, so take a moment to test the assumptions against the data and move quickly if you decide the story fits your plan, starting with the 3 key rewards.

Ready To Hunt For More Investment Ideas?

If this story has sharpened your thinking, do not stop here. Put that momentum to work by scanning other opportunities with focused stock lists built from hard numbers.

• Target potential bargains that combine quality with attractive pricing by checking out the 59 high quality undervalued stocks.
• Zero in on companies built on stronger foundations by reviewing the solid balance sheet and fundamentals stocks screener (40 results).
• Spot opportunities others may be overlooking by running through the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.